Research programme: phosphatidylinositol 3-kinase inhibitors - Exelixis/sanofi-aventis

Drug Profile

Research programme: phosphatidylinositol 3-kinase inhibitors - Exelixis/sanofi-aventis

Latest Information Update: 13 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis; sanofi-aventis
  • Developer Exelixis; Sanofi
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Dec 2011 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
  • 16 Nov 2010 Preclinical pharmacodynamics data presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010) (AACR-2010)
  • 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top